Stoke Therapeutics, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Stoke Therapeutics, Inc. (STOK) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $5.08 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-10.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2022-03-10
- Stoke Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-12-31 was $0.00.
- Stoke Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-09-30 was $0.00.
- Stoke Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-06-30 was $0.00.
- Stoke Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-03-31 was $2.15M.
- Stoke Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $5.08M, a 136.00% increase from fiscal 2020.
- Stoke Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $2.15M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2021-12-31 | $5.08M 10-K · filed 2022-03-10 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $0.00 derived: sum of 2 quarters · filed 2022-03-10 | $0.00 derived: sum of 3 quarters · filed 2022-03-10 | $2.15M 10-K · filed 2022-03-10 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $0.00 derived: sum of 2 quarters · filed 2021-11-08 | $2.15M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $2.15M 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $2.15M 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |